Quick Answer
Serina Therapeutics, Inc. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025.
Serina Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.91 | -26.5% |
| 2024 | -$1.51 | -306.8% |
| 2023 | $0.73 | +107.5% |
| 2022 | -$9.70 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.45 | -446.2% | +31.8% |
| June 30, 2025 | -$0.66 | -229.4% | -34.7% |
| March 31, 2025 | -$0.49 | +90.9% | -476.9% |
| September 30, 2024 | $0.13 | -43.5% | -74.5% |
| June 30, 2024 | $0.51 | +363.6% | +109.5% |
| March 31, 2024 | -$5.38 | -2790.0% | -2439.1% |
| September 30, 2023 | $0.23 | +483.3% | +109.1% |
| June 30, 2023 | $0.11 | +257.1% | -45.0% |
- Serina Therapeutics, Inc. showed a decrease of -26.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Serina Therapeutics, Inc.’s diluted eps has grown by 80.3% (from $9.70 per share (loss) to $1.91 per share (loss)).
- The most recent figure is from Serina Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: